Molecular Profiling: Genomic-Guided Therapy for Lung Adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) often presents at advanced stages with poor prognosis.
• Molecular alterations, including MET exon 14 skipping mutations, are key therapeutic targets in NSCLC.
• Precision medicine approaches are transforming NSCLC treatment paradigms.

Observation:

• An 83-year-old patient with stage 4A metastatic lung adenocarcinoma and a history of COPD was diagnosed with a MET exon 14 skipping mutation.
• The patient received capmatinib, a selective MET tyrosine kinase inhibitor (TKI).

Findings:

• Capmatinib treatment led to sustained disease stability and tumor shrinkage over a three-year follow-up period.
• The patient tolerated capmatinib well, with no significant adverse events reported.
• Durable disease control was achieved, offering an alternative to traditional chemotherapy.

Implications:

• This case underscores the importance of molecular testing for identifying actionable mutations like MET exon 14 skipping in NSCLC.
• Capmatinib demonstrates efficacy and tolerability in elderly patients with comorbidities, supporting its use in this population.
• Integrating precision oncology, specifically MET TKIs, can significantly improve outcomes for patients with advanced NSCLC and MET alterations.